spot_img

about fansalaran

FanSalaran is a comprehensive media platform dedicated to reporting and clarifying the significant achievements of pharmaceutical companies. In collaboration with passionate and motivated young journalists, this website consistently strives to showcase the country's successes in order to inspire and encourage the hardworking individuals of this land.

Oral Antidiabetic Drugs Market to Reach $86.92 Billion by 2029 with 6.8% CAGR

What Is The Estimated Industry Size Of Oral Antidiabetic Drugs Market?

The market size for oral antidiabetic medication has seen powerful growth in the past few years. The value is projected to rise from $62.25 billion in 2024 to $66.73 billion in 2025, reflecting a compound annual growth rate (CAGR) of 7.2%. The past growth can be credited to the heightened occurrence of diabetes, better knowledge about managing the disease, an increase in the elderly population, expanded accessibility of advanced oral antidiabetic drugs, and developments in healthcare infrastructure.

The market size for oral antidiabetic drugs is anticipated to experience robust growth in the upcoming years, reaching $86.92 billion in 2029 with a compound annual growth rate (CAGR) of 6.8%. The escalation for the projected period is tied to factors like the increasing utilization of new oral antidiabetic therapies, significant investments in diabetes research and development, growing demand for affordable diabetes management solutions, increasing instances of type 2 diabetes worldwide, and a heightened emphasis on personalized medicine for diabetes treatment. Anticipated trends for the forecast period consist of the progression in drug delivery technologies, pioneering efforts in composite therapies, adoption of digital health instruments for diabetes regulation, fabrication of safer and more competent oral antidiabetic drugs, and advancements in tailored treatment methodologies.

Hot this week

Novo Nordisk Lowers Full-Year Profit Guidance in New CEO’s Maiden Quarter

Wegovy-maker Novo Nordisk lowered its full-year profit forecast on...

Compass Pathways to expedite launch timing of its experimental depression therapy

Drug developer Compass Pathways said on Tuesday it is...

Pharma Investment to establish manufacturing facility at SOHAR Freezone

SOHAR Port and Freezone has signed a land lease...

Novo Nordisk, Pfizer sweeten bid for Metsera as bidding war heats up

Novo Nordisk and Pfizer have revised their bids for...

Topics

spot_img

Related Articles

Popular Categories

spot_imgspot_img